CareLit · DOI-Nachweis · Pneumologie
ENCORE: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs. crizotinib (CZ) in untreated advanced ALK+ NSCLC
DOI 10.1055/s-0039-1678027
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Thomas, DR Camidge, S Peters, T Mok, SM Gadgeel, P Cheema, N Pavlakis, F De Marinis, D Stroyakovskii, BC Cho, L Zhang, D Moro-Sibilot, A Zeaiter, E Mitry, B Balas, B Müller, AT Shaw
ZeitschriftPneumologie
AusgabeS 01 S 01/2019
Jahrgang / SeitenJg. 73
Kernaussage aus der Literatur
Abstract-Vorschau
ENCORE: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs. crizotinib (CZ) in untreated advanced ALK+ NSCLC
Zitieren
Zitierempfehlung
M Thomas, DR Camidge, S Peters, T Mok, SM Gadgeel, P Cheema, N Pavlakis, F De Marinis, D Stroyakovskii, BC Cho, L Zhang, D Moro-Sibilot, A Zeaiter, E Mitry, B Balas, B Müller, AT Shaw (2019) ENCORE: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs. crizotinib (CZ) in untreated advanced ALK+ NSCLC. Pneumologie, 73 (S 01 S 01). https://doi.org/10.1055/s-0039-1678027
Mit CareLit weiterarbeiten